Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos

H1200000

Hydrochlorothiazide

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

6-Chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide, 6-Chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C7H8ClN3O4S2
Número CAS:
58-93-5
Peso molecular:
297.74
Número MDL:
MFCD00051765
Código UNSPSC:
41116107
ID de substância PubChem:
329815156
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

hydrochlorothiazide

fabricante/nome comercial

EDQM

aplicação(ões)

pharmaceutical (small molecule)

formato

neat

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl

InChI

1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)

chave InChI

JZUFKLXOESDKRF-UHFFFAOYSA-N

Informações sobre genes

human ... SLC12A3(6559)

Procurando produtos similares? Visita Guia de comparação de produtos

Categorias relacionadas

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Hydrochlorothiazide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Ações bioquímicas/fisiológicas

Carbonic anhydrase inhibitor

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

Pictogramas

Health hazard
GHS08

Palavra indicadora

Warning

Frases de perigo

H351

Classificações de perigo

Carc. 2

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 2

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Choose from one of the most recent versions:

Certificados de análise (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 4

1 of 4

4-Amino-6-chloro-1,3-benzenedisulfonamide 98%

Sigma-Aldrich

308560

4-Amino-6-chloro-1,3-benzenedisulfonamide

Chlorothiazide Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1179

Chlorothiazide

Valsartan Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1315

Valsartan

Diclofenac sodium salt analytical standard

Supelco

93484

Diclofenac sodium salt

Soham Rej et al.
Drugs & aging, 31(12), 911-916 (2014-10-22)
Little is known about how lithium should be dosed to achieve therapeutic but safe serum concentrations in older adults. In this paper, we investigate how the lithium dose-concentration ratio changes across the lifespan. This was a cross-sectional analysis of 63
Dragos Vinereanu et al.
American heart journal, 168(4), 446-456 (2014-09-30)
The objective of this study is to compare the effects of 2 types of diuretics, indapamide and hydrochlorothiazide, added to an angiotensin-converting enzyme inhibitor, on ventricular and arterial functions in patients with hypertension and diabetes. This is a prospective, randomized
James J DiNicolantonio
Expert opinion on pharmacotherapy, 13(6), 807-814 (2012-03-20)
Hydrochlorothiazide (HCTZ) has not been shown to reduce mortality or cardiovascular events when given as a single agent. In fact, HCTZ increased cardiovascular death and coronary artery disease (CAD) compared to placebo and usual care in 2 randomized trials, yet
Sverre E Kjeldsen et al.
Journal of clinical hypertension (Greenwich, Conn.), 15(6), 380-388 (2013-06-05)
Older patients frequently receive angiotensin II receptor blocker/diuretic combinations to control blood pressure (BP), although there have been relatively few trials specifically examining this patient population. A pooled analysis was performed of data from 7 randomized trials of telmisartan/hydrochlorothiazide combinations
Edgar V Lerma
Current hypertension reports, 13(5), 386-395 (2011-07-29)
Hypertension remains an important problem that increases the risk of cardiovascular disease and is a leading cause of mortality worldwide. Achieving long-term control of arterial hypertension, which has an estimated prevalence of 28% in the US adult population, would translate
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica